Everest Medicines Limited (FRA:6HN)

Germany · Delayed Price · Currency is EUR

4.860

+0.040 (0.83%)

At close: Dec 4, 2025

-6.54% (1Y)

Market Cap	1.77B
Revenue (ttm)	101.18M
Net Income (ttm)	-78.30M
Shares Out	n/a
EPS (ttm)	-0.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	4.860
Previous Close	4.820
Day's Range	4.860 - 4.860
52-Week Range	4.480 - 8.250
Beta	n/a
RSI	40.63
Earnings Date	Nov 28, 2025

About Everest Medicines

Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2017

Employees 665

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 6HN

Full Company Profile

Financial Performance

In 2024, Everest Medicines's revenue was 706.68 million, an increase of 461.16% compared to the previous year's 125.93 million. Losses were -1.04 billion, 23.3% more than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.